Follow Viking Therapeutics to never miss an important update.
Viking finalized the details of its recent fundraising, which closed on September 25. The company sold about 9 million new shares of stock at 35 dollars each, raising roughly 297 million dollars. It also issued 258 million dollars in convertible notes, which are a type of debt that can later be turned into shares of stock.
For a biotechnology company that does not yet have a product on the market, cash is everything. This move significantly boosts Viking's bank account, giving it the money needed to fund expensive late-stage clinical trials for its obesity drugs without having to worry about running out of cash in the near term.
Source: 8-K filing
Oppenheimer raised its price target for the company from $100 to $120. This move follows a week where the company reported strong weight-loss data and raised $500 million to fund its drug development. The new target is well above the current average analyst target of $98. While price targets are just estimates of where a stock might trade, this change reflects growing confidence in the company's obesity drug pipeline. The firm is betting that the company's recent progress makes it a more formidable challenger to the larger players currently dominating the weight-loss market.
Source: Oppenheimer
Viking reported strong results for its obesity drug, VK2735, which targets two different hunger-regulating hormones. Patients taking a weekly dose lost about 22 percent of their body weight over 33 weeks. The study also showed that patients who switched to less frequent doses, like once every two weeks or once a month, were able to keep almost all of that weight off.
This is a big deal because it suggests the drug could be more convenient than the weekly injections currently sold by Eli Lilly and Novo Nordisk. If patients only need a shot once a month to maintain their weight loss, it would likely make the drug much more popular and easier to stick with. The results keep Viking on track as the most serious challenger to the two companies that currently dominate the market.
Source: PRNewsWire
Viking is raising about 500 million dollars by selling new shares at 35 dollars each and issuing convertible notes, which are a type of debt that can later be turned into stock. The stock fell about 15 percent on the news, which often happens when a company issues new shares because it dilutes the value for existing owners.
While the price drop is painful for now, this is a standard move for a biotech company that does not yet have a product on the market. Developing new drugs is expensive, and this cash gives Viking more time to finish its large-scale trials. The company already had about 600 million dollars in the bank, so this extra cushion significantly extends how long it can operate before needing more funding.
Source: PRNewsWire
The company reported a loss of about $1.10 per share, which was slightly better than the $1.23 loss analysts expected. Because Viking is a clinical-stage biotech, it has no sales yet and spends its cash on research and drug trials. It ended the quarter with $502 million in cash, which is enough to fund its work for several years.
The most important news is that the Phase 3 trials for its injectable obesity drug are now fully enrolled. This is a critical final step before seeking government approval. Additionally, the company plans to start Phase 3 trials for its oral version by the end of the year. If the oral pill proves as effective as the injections, it could be a major advantage over current market leaders that require weekly shots.
See the full quarter, and how our tracked metrics did
Source: 8-K filing
Management has struggled to forecast the high costs of running large drug trials, missing their own targets for six of the last eight quarters. This makes their spending estimates less reliable than their clinical data.
| Expectation | |
|---|---|
| EPS | $-1.07 |
| Revenue | — |
Follow Viking Therapeutics to get the latest and most important updates.
Follow VKTX